Effect of the essential oil of Chrysactinia mexicana A. Gray on clinical isolates of Candida glabrata
The objective of this work was to evaluate the effect of the Chrysactinia mexicana A. Gray essential oil, on C. glabrata clinical isolates. The essential oil was obtained by steam entrainment of flowers, leaves and secondary branches of C. mexicana. Gas chromatography and mass spectrometry were perf...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| 格式: | Online |
| 語言: | spa |
| 出版: |
Universidad de Sonora
2021
|
| 在線閱讀: | https://biotecnia.unison.mx/index.php/biotecnia/article/view/1265 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 總結: | The objective of this work was to evaluate the effect of the Chrysactinia mexicana A. Gray essential oil, on C. glabrata clinical isolates. The essential oil was obtained by steam entrainment of flowers, leaves and secondary branches of C. mexicana. Gas chromatography and mass spectrometry were performed to determine the oil composition. Logarithmic and stationary phase microdilution assays were performed with Saccharomyces cerevisiae and clinical isolates of C. glabrata to determine the Minimum Inhibitory Concentration (MIC) of the oil. The cultures were incubated in liquid YPD medium, for 7 h in fresh medium (logarithmic phase) or 3 h in recovering medium (stationary phase), with the oil and microdilution tests were performed. The three main oil compounds identified were piperitone (29.57%), eucalyptol (26.86%) and α-terpineol (14.65%). The MICs obtained were, a) stationary phase: S. cerevisiae (BY4741) 2.78 mg/mL and C. glabrata (CBS138), (NY66) and (AN400) 6.50 mg/mL and (NY62) 9.29 mg/mL; b) logarithmic phase: S. cerevisiae (BY4741) 3.71 mg/mL and C. glabrata (CBS138) 4.64 mg/mL, (NY66) 6.5 mg/mL, (AN400) 8.36 mg/mL, and (NY62) 18.5 mg/ mL. This work constitutes the first report of the fungicidal effect of the C. mexicana essential oil on human pathogenic fungi such as C. glabrata. |
|---|
